BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17595491)

  • 1. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
    Azad R; Chandra P
    Indian J Ophthalmol; 2007; 55(4):319; author reply 320. PubMed ID: 17595491
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label use of bevacizumab in retinopathy of prematurity.
    Rishi E; Rishi P; Ratra D; Bhende M
    Retina; 2009 Feb; 29(2):284; author reply 284-5. PubMed ID: 18854784
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity.
    Sangtam T; Vinekar A; Maheshwar B; Dogra MR; Eong KG
    Indian J Ophthalmol; 2007; 55(4):317; author reply 317-8. PubMed ID: 17595489
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
    Travassos A; Teixeira S; Ferreira P; Regadas I; Travassos AS; Esperancinha FE; Prieto I; Pires G; van Velze R; Valido A; Machado Mdo C
    Ophthalmic Surg Lasers Imaging; 2007; 38(3):233-7. PubMed ID: 17552391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
    Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P
    Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118
    [No Abstract]   [Full Text] [Related]  

  • 6. A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination.
    Patel CK; Walker NJ; Kam JK
    Br J Ophthalmol; 2010 Aug; 94(8):1107-9. PubMed ID: 20558426
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
    Law JC; Recchia FM; Morrison DG; Donahue SP; Estes RL
    J AAPOS; 2010 Feb; 14(1):6-10. PubMed ID: 20227614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Hosseini H; Khalili MR; Nowroozizadeh S
    Retina; 2009 Apr; 29(4):562. PubMed ID: 19262431
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Nowroozzadeh MH
    Retina; 2009 Apr; 29(4):564-5; author reply 565-8. PubMed ID: 19262428
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 11. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual acuity and electroretinography findings 3 ½ years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity.
    Shah PK; Morris RJ; Narendran V; Kalpana N
    Indian J Ophthalmol; 2011; 59(1):73-4. PubMed ID: 21157086
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
    Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
    J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab for retinopathy of prematurity.
    Lim LS; Mitchell P; Wong TY
    N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity.
    de Klerk TA; Park DY; Biswas S
    Eye (Lond); 2013 Oct; 27(10):1218. PubMed ID: 23846376
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab for retinopathy of prematurity.
    Gilbert CE; Zin A; Darlow B
    N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.